A 52-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA)

16394EFC17872OpenA 52-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA)IndustrialAdultTreatmentIIIOtherBroome, CatherineGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Medicine Hem-Onc2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>